Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176423 · ClinicalTrials.gov registry record · Phase 4
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 117
- Enrollment target
NCT00176423 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 117 participants.
The verdict
NCT00176423, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 117 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.
Interventions
- DRUG galantamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2002-05 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176423
The ClinicalTrials.gov registry entry for NCT00176423 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which galantamine is the first listed.
NCT00176423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176423 about?
NCT00176423 is a clinical study titled "Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia". The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.
What is the current status of trial NCT00176423?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 117 participants. The study started on 2002-05. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00176423?
The interventions under investigation include: galantamine (DRUG).
Who is sponsoring clinical trial NCT00176423?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.